Key Takeaways

  • Anthem’s new policy establishes medical necessity criteria for ocular pressure adjusting pump systems in eligible adults with open-angle glaucoma

  • FSYX demonstrated a 39.1% mean reduction in nocturnal IOP during device use in the 52-week HERCULES study

  • The policy provides a potential reimbursement pathway, although individual coverage remains subject to plan requirements

Anthem has published a new medical policy establishing clinical criteria under which ocular pressure adjusting pump systems, including Balance Ophthalmics’ FSYX Ocular Pressure Adjusting Pump (OPAP), may be considered medically necessary for eligible adults with open-angle glaucoma, including normal-tension glaucoma, according to a Balance news release.

The policy, "DME.00055, Ocular Pressure Adjusting Pump Systems," was published October 1, 2026, following review by Anthem’s Medical Policy & Technology Assessment Committee.

Under the policy, ocular pressure adjusting pump systems may be considered medically necessary as adjunctive therapy to reduce IOP during sleep when patients meet specified criteria. These include a daytime IOP of 21 mm Hg or less in at least 1 treated eye, current or previous use of another IOP-lowering treatment, and a need for additional pressure reduction to achieve an individualized target IOP or reduce the risk of glaucomatous progression.

The policy also outlines continued-use criteria requiring documented clinical benefit and ongoing medical necessity. Coverage remains subject to individual plan benefits and authorization requirements, and the policy does not guarantee reimbursement.

The announcement follows the October 1 effective date of dedicated HCPCS Level II codes for ocular pressure adjusting pump systems. Code E2403 identifies an external ocular negative pressure pump, while A6614 covers associated supplies and accessories.

FSYX is a prescription-only, noninvasive therapy that uses pressure-modulating goggles connected to a compact pump to apply negative pressure to the eyes during sleep.

Anthem’s policy cites clinical evidence from the HERCULES and EXPLORER studies. In the 52-week HERCULES study, FSYX demonstrated a 39.1% mean reduction in nocturnal IOP during device use.¹ Across the principal studies reviewed by Anthem, no device-related serious adverse events were reported.

Reference

1. Ferguson TJ, Samuelson TW, Herndon LW, et al. Negative pressure application by the ocular pressure adjusting pump to lower intraocular pressure in normal-tension glaucoma: HERCULES study. Am J Ophthalmol. 2025;275:121-134. doi:10.1016/j.ajo.2025.03.034.